NCT00632086

Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers

A Phase 1, Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Aspirin Administered as PA32540 (Aspirin/Omeprazole) or as the Aspirin Component of PA32540 or as Ecotrin® 325 mg in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: POZEN · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Study to determine a single dose bioavailablity of PA32540 is similar to EC aspirin 325 mg with respect to salicylic acid.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PA32540
DRUG	aspirin component of PA32540	The 325 mg aspirin component of PA32540
DRUG	Ecotrin	325 mg Ecotrin

Timeline

• Start date: 2008-02-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2008-03-10
• Last updated: 2008-03-10